Regulatory & Devices
Medicare’s New RAPID Pathway: Closing the Coverage Gap
By Intent.Health Team • April 23, 2026
What’s happening
CMS and the FDA have just announced the RAPID Coverage Pathway (Regulatory Alignment for Predictable and Immediate Device coverage). This initiative is designed to slash the "valley of death" the period between FDA approval and Medicare reimbursement, from 12+ months down to just 60–90 days.
What’s changing / Business impact
- Accelerated Commercialization: Faster reimbursement timelines mean manufacturers reach "day-one" revenue sooner, improving R&D ROI.
- Evidence Alignment: Linking FDA and CMS experts early ensures clinical data satisfies both safety and value requirements.
- Investment Predictability: Reduces capital risk for neurotech, cardiac implants, and AI-driven diagnostics.
Why this matters
Device innovation has historically been throttled by the CMS coverage backlog, not the FDA approval desk.
This policy shift signals that:
- Regulatory and reimbursement alignment is becoming a foundational layer of the U.S. healthcare system.
- The bottleneck is shifting from approval-driven speed to coverage-driven adoption.